androgen deprivation therapy (ADT) 비교 | 바이오정보모아

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

Overview MoA Clinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목	AntibodyLimited DatastalePhase 3 ADT (androgen deprivation therapy, androgen deprivation therapy (ADT)) Istituto Clinico Humanitas·Oligorecurrent and Oligoprogressiv… 146 trials

Overview Program	androgen deprivation therapy (ADT)
Overview Company	Istituto Clinico Humanitas
Overview Modality	ANTIBODY
Overview Target	Oligorecurrent and Oligoprogressive Pros
Overview Indication	Prostate Cancer
Overview Phase	PHASE_3
Overview Status	RECRUITING
Overview Content status	Limited Data
Overview Data Confidence	Editorial scope · limited data
Overview Development Signal	Development Signal · Emerging
Overview Approval status	Investigational

MoA Mechanism	targeting Vβ6 and Vβ10 T-cell receptor
MoA Biomarker	biomarker-driven studies in larger cohorts to refine treatment strategies

Clinical Program phase	PHASE_3
Clinical Trial activity	No active/completed counts

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

Overview MoA Clinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목	AntibodyLimited DatastalePhase 3 ADT (androgen deprivation therapy, androgen deprivation therapy (ADT)) Istituto Clinico Humanitas·Oligorecurrent and Oligoprogressiv… 146 trials

Overview Program	androgen deprivation therapy (ADT)
Overview Company	Istituto Clinico Humanitas
Overview Modality	ANTIBODY
Overview Target	Oligorecurrent and Oligoprogressive Pros
Overview Indication	Prostate Cancer
Overview Phase	PHASE_3
Overview Status	RECRUITING
Overview Content status	Limited Data
Overview Data Confidence	Editorial scope · limited data
Overview Development Signal	Development Signal · Emerging
Overview Approval status	Investigational

MoA Mechanism	targeting Vβ6 and Vβ10 T-cell receptor
MoA Biomarker	biomarker-driven studies in larger cohorts to refine treatment strategies

Clinical Program phase	PHASE_3
Clinical Trial activity	No active/completed counts